Shayma Kazmi, MD, medical oncologist, Cancer Treatment Centers of America, Eastern Regional Medical Center, discusses olanzapine for breakthrough chemotherapy-induced nausea and vomiting.

A Phase III trial to be presented at ASCO found that in cancer patients with chemotherapy-induced nausea and vomiting (CINV) that does not respond to conventional treatments, olanzapine was effective in controlling side effects.

Kazmi says that, in the past, antipsychotic medications such as haldol and haloperidol were used to control CINV. However, those medications tended to have undesirable side effects, with fatigue being the most common.

Olanzapine is a newer antipsychotic medication used to help control CINV. The drug affects the nausea center in the brain as a side effect, but how it does so is unknown. Olanzapine also helps patients with sleep, so it can be used in patients with severe insomnia as well.

Conference

® Conference page includes a listing of all conferences covered by 

, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.


Supportive Care

The OncLive Supportive Care condition center page is a comprehensive resource for clinical news and expert insights on supportive care and management of patients with cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, best practices, and ongoing research as it relates to supportive care for patients with cancer.

ASCO Annual Meeting

Dr. Shayma Kazmi, from Cancer Treatment Centers of America, on Olanzapine for Breakthrough Chemotherapy-Induced Nausea and Vomiting

Dr. Kazmi Discusses Olanzapine for Breakthrough CINV